Cumberland Pharmaceuticals (NASDAQ:CPIX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research report sent to investors on Wednesday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Price Performance

Shares of NASDAQ:CPIX opened at $1.76 on Wednesday. The company has a market capitalization of $24.96 million, a PE ratio of -4.00 and a beta of 0.16. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.11 and a current ratio of 1.28. The stock has a fifty day moving average of $1.84 and a 200-day moving average of $1.88. Cumberland Pharmaceuticals has a one year low of $1.43 and a one year high of $2.36.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its earnings results on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter. Cumberland Pharmaceuticals had a negative net margin of 15.87% and a positive return on equity of 6.84%. The company had revenue of $9.35 million for the quarter.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

A hedge fund recently bought a new stake in Cumberland Pharmaceuticals stock. Bank of New York Mellon Corp bought a new stake in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 75,268 shares of the specialty pharmaceutical company’s stock, valued at approximately $142,000. Bank of New York Mellon Corp owned about 0.52% of Cumberland Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 15.51% of the company’s stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.